Recursion Pharmaceuticals

19 articles with Recursion Pharmaceuticals

• 

  Artificial Intelligence Gaining Ground in Drug Development

  2/11/2019

  It’s not exactly breaking news that biopharma companies are increasingly turning toward machine learning and artificial intelligence (AI) to improve drug development. What is big news is how resoundingly it might improve on traditional methods.

• Recursion Announces Options Exercise by Takeda and Extension of AI-enabled Drug Discovery Collaboration

  1/7/2019

  From collaboration to licensing options in less than 18 months

• Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process

  11/8/2018

  Follows the successful completion of milestones set in the initial Phase 1 grant for $223,000, awarded in 2016.

• Recursion Pharmaceuticals Named One of Utah's 2018 Top Workplaces by The Salt Lake Tribune

  11/5/2018

  Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, has been awarded a 2018 Top Workplaces award by The Salt Lake Tribune.

• Veteran Biopharma Operations Leader Tina M. Larson to Join Recursion as Chief Operating Officer

  7/10/2018

  Recursion announced the company has appointed Tina M. Larson as Chief Operating Officer.

• Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation

  7/10/2018

  Recursion announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1 clinical trial of REC-994 in the treatment of cerebral cavernous malformation (CCM).

• Medicinal Chemistry Leaders Drs. Phil Carpino and Mike Genin Form New Chemistry Team at Recursion Pharmaceuticals

  5/15/2018

  Recursion Pharmaceuticals, today announced that it has hired Phil Carpino, Ph.D. and Mike Genin, Ph.D., to direct chemistry efforts.

• Pharmaceutical Business Development Leader Dr. Kevin Lynch Joins Recursion as Chief Business Officer

  5/1/2018

  Recursion Pharmaceuticals is a biotechnology company that combines artificial intelligence, experimental biology, and automation to discover drugs at scale

• Recursion, Takeda Ink $90 Million AI R&D Pact

  10/11/2017

• Recursion Scores $60 Million to Fund AI-Driven Drug Repurposing, Pipeline Development

  10/4/2017

• Dr. Chand Sishta To Lead Regulatory Affairs For Recursion Pharmaceuticals

  6/29/2017

• Yolanda Chong Joins Recursion Pharmaceuticals To Advance Discovery Platform

  4/18/2017

• Recursion Pharmaceuticals Raises Additional Funding, Bringing Total Series A To $15.05 Million For Drug Discovery

  11/22/2016

• Recursion Pharmaceuticals Selects Anaconda To Create Innovative Next Generation Drug Discovery Assay Platform To Eradicate Rare Genetic Diseases

  10/26/2016

• Recursion Pharmaceuticals Announces John Pereira, MBA As Chief Operating Officer

  10/25/2016

• Recursion Pharmaceuticals Raises $13M To Discover New Drugs Using Artificial Intelligence

  10/3/2016

• Recursion Pharmaceuticals Announces Research Agreement With Sanofi Genzyme

  4/25/2016

• Recursion Pharmaceuticals Wins $1.5 Million NIH Grant For Rare Disease Drug Discovery

  2/25/2015

• Recursion Pharmaceuticals Announces Robert Lollini As The Second Member Of Business Advisory Panel

  11/3/2014